

**HBV Forum 10**  
**Tuesday June 20, 2023**  
 ARCOTEL Wimberger Wien  
 Neubaugürtel 34-361070 Vienna Austria

**AGENDA**

12:00 PM	<b>Registration and Lunch</b>	
1:00 PM	Housekeeping	<i>Paula Blay, Prism Event Management</i>
1:05 PM	Welcome from the Forum	<i>Mitchell Leus, Forum for Collaborative Research</i>
1:15 PM	Introductory Remarks: HBV Forum Chairs	<i>Veronica Miller, Forum for Collaborative Research Marion Peters*, Northwestern University Oliver Lenz, Janssen Pharmaceuticals</i>
<b>Session I: Working Group Updates</b>		
<b>Moderators: Veronica Miller, Forum for Collaborative Research and Oliver Lenz, Janssen Pharmaceuticals</b>		
1:20 PM	Stopping Finite Treatment Manuscript	<i>Marion Peters*, Northwestern University</i>
1:25 PM	Advocate Perspective on Finite Treatment	<i>Chari Cohen, Hepatitis B Foundation Jessica Hicks, World Hepatitis Alliance</i>
1:30 PM	HDV RNA Assays Manuscript	<i>Norah Terrault, University of Southern California Heiner Wedemeyer*, Hannover Medical School</i>
1:45 PM	Advocate Perspective on HDV Therapeutic Development	<i>Chari Cohen, Hepatitis B Foundation Jessica Hicks, World Hepatitis Alliance</i>
1:50 PM	Open Discussion	<i>All Meeting Participants</i>
<b>Session II: MAPPED (Mechanisms of Action and Patient Populations: Emphasizing Diversity) Working Group</b>		
<b>Moderators: Jordan Feld, Toronto Centre for Liver Disease and Michael Biermer, Janssen Pharmaceuticals</b>		
2:20 PM	MAPPED Working Group	<i>Jordan Feld, Toronto Centre for Liver Disease Michael Biermer, Janssen Pharmaceuticals</i>
2:30 PM	Panel Discussion – MAPPED Working Group	<i>Chari Cohen, Hepatitis B Foundation Sue Currie, Virion Therapeutics Grace Dolman, GlaxoSmithKline Jessica Hicks, World Hepatitis Alliance Carey Hwang, Vir Biotechnology Pietro Lampertico, University of Milan Jean-Michel Pawlotsky, University of Paris-Est</i>
2:50 PM	Open Discussion	<i>All Meeting Participants</i>
3:20 PM	<b>Break</b>	
<b>Session III: Challenges in PD-1 and PD-L1 Therapies</b>		
<b>Moderators: Marion Peters*, Northwestern University and Ed Gane, University of Auckland</b>		
3:40 PM	Overview on Challenges in PD-1 & PD-L1 HBV Trials	<i>Adam Gehring, ICE-HBV, Toronto Centre for Liver Disease</i>
3:50 PM	Open Discussion	<i>All Meeting Participants</i>
<b>Session IV: Current and Future Landscape of HBV Biomarkers</b>		
<b>Moderators: Veronica Miller, Forum for Collaborative Research, Doug Mayers*, Independent Consultant and Markus Cornberg, Hannover Medical School</b>		
4:10 PM	Biomarkers Working Group	<i>Mitchell Leus, Forum for Collaborative Research</i>
4:25 PM	Open Discussion	<i>All Meeting Participants</i>

**HBV Forum 10**  
**Tuesday June 20, 2023**  
ARCOTEL Wimberger Wien  
Neubaugürtel 34-361070 Vienna Austria

**AGENDA**

<b>Session V: Frontiers in HBV Drug Development</b>		
<b>Moderators: Robert Gish, Hepatitis B Foundation and Veronica Miller, Forum for Collaborative Research</b>		
5:05 PM	Overview on Long-Acting HBV Treatments	<i>David Thomas*</i> , Johns Hopkins University
5:15 PM	Patient Perspective on Long-Acting HBV Treatments	<i>Danjuma Adda**</i> , World Hepatitis Alliance <i>Su Wang**</i> , Center for Asian Health, Saint Barnabas Medical Center <i>Thomas Tu**</i> , Westmead Institute for Medical Research, Hepatitis B Voices Australia HepBCommunity.org
5:30 PM	FDA Perspective on Long-Acting HBV Treatments	<i>Poonam Mishra</i> , U.S. Food and Drug Administration <i>Jonathan Rawson</i> , U.S. Food and Drug Administration
5:40 PM	EMA Perspective on Long-Acting HBV Treatments	<i>Stephanie Buchholz</i> , European Medicines Agency
5:50 PM	Open Discussion	<i>All Meeting Participants</i>
6:25 PM	Meeting Wrap Up and Adjourn	
6:30 PM	<b>HBV Forum, Liver Forum and PSC Forum Evening Reception</b>	

\* Indicates remote participation

\*\* Indicates pre-recorded presentation

**QR Code: HBV Forum 10 Feedback Form**

